This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Tyra Biosciences’s 8K filing here.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- Stock Analyst Ratings and Canadian Analyst Ratings
- GM’s Lithium Americas Deal Positions It for EV Dominance
- Basic Materials Stocks Investing
- Amazon: Why Analysts Think It’s A Solid Buy Ahead Of Earnings
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- NextEra’s Diverse Business Is Set to Win As Energy Demand Rises
